問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberSMX 22-002
NCT Number(ClinicalTrials.gov Identfier)-
Active

2024-01-01 - 2026-12-31

Phase III

Recruiting7

ICD-10D05.00

Lobular carcinoma in situ of unspecified breast

ICD-10D05.01

Lobular carcinoma in situ of right breast

ICD-10D05.02

Lobular carcinoma in situ of left breast

ICD-10D05.10

Intraductal carcinoma in situ of unspecified breast

ICD-10D05.11

Intraductal carcinoma in situ of right breast

ICD-10D05.12

Intraductal carcinoma in situ of left breast

ICD-10D05.80

Other specified type of carcinoma in situ of unspecified breast

ICD-10D05.81

Other specified type of carcinoma in situ of right breast

ICD-10D05.82

Other specified type of carcinoma in situ of left breast

ICD-10D05.90

Unspecified type of carcinoma in situ of unspecified breast

ICD-10D05.91

Unspecified type of carcinoma in situ of right breast

ICD-10D05.92

Unspecified type of carcinoma in situ of left breast

ICD-9233.0

Carcinoma in situ of breast

-

  • Trial Applicant

    MEDPACE TAIWAN LIMITED

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/05/13

Investigators and Locations

Principal Investigator 戴明燊

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

The Actual Total Number of Participants Enrolled

0 Recruiting

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 鍾奇峰

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 陳守棟

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wei-Pang Chung

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

The Actual Total Number of Participants Enrolled

0 Recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

-

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    21 participants

  • Global

    500 participants